Does it need to Take Digitally Targeted Biopsies Additionally to TRUS Guided 12- Core Systematic Prostate Biopsies? A Single Center Prospective Clinical Study
Journal Title: Open Access Journal of Urology & Nephrology - Year 2019, Vol 4, Issue 1
Abstract
Purpose: To investigate whether digitally targeted additional biopsies enhance the detection rate of standard 12-core TRUS guided systematic biopsies. Methods: A total of 119 patients who either have a PSA level greater than 4ng/ml or suspicious DRE regardless of their PSA level underwent a twelve cores TRUS guided standard systematic prostate biopsies and two additional DRE guided targeted biopsies in case of abnormal DRE. The patients were divided into three groups with regards to their PSA level; Group I (n=8): PSA<4ng/ml, Group II (n=62): PSA 4-10ng/ml and Group III (n=49): PSA>10ng/ml. In each group, the independent diagnostic yield of DRE guided biopsies was compared to the standard systematic biopsies. The Results: Group I: In 3 out of 8 patients in this group were diagnosed as poorly differentiated prostate cancer. DRE guided biopsies detected one cancer out of 2 in this group. Group II: TRUSG guided systematic biopsies revealed 6 prostate cancer out of 7 cancer cases. DRE guided biopsies were also positive for prostate cancer in only 1 case, while standard 12-core systematic biopsies had failed to depict the cancer. Group III: Both TRUSG guided systematic biopsies and DRE guided biopsies revealed prostate cancer in all 17 cases. DRE guided biopsies did not increase the detection rate of systematic biopsies in this group. Conclusion: Digitally guided biopsies additionally taken to systematic 12-core biopsies do not enhance the detection rate of prostate cancer in the patients with a PSA level greater than 20ng/ml, possibly due to a large volume disease, however, it may be a useful adjunct for the patients with a PSA level less than 10ng/ml as well as in the presence of undifferentiated tumors.
Authors and Affiliations
Sarp Korcan Keskin
Keywords
Related Articles
- EP ID EP516002
- DOI -
- Views 69
- Downloads 0
Utilization of the Charlson Comorbidity Score to Predict 10-Year Survival in Renal Transplant Recipients
Purpose: The Charlson Comorbidity Score has been demonstrated to predict mortality in prostate cancer patients. Our novel objective was to compare the 10-year observed mortality with expected mortality based on pre-opera...
Decrease in Quality of Life and Functional Assessment in Elder Patients with End-Stage Renal Disease after Two Years of Hemodialysis Therapy
Introduction: Hemodialysis improves survival rates of Chronic Kidney Disease (CKD) patients but not Quality of Life (QoL) which decreases in a more aggressive way in the elderly population. We describe the reduction and...
Application of PSA Kinetics on Prostate Cancer: Experience of Pharmacovigilance Department of University Hospital Establishment of ORAN (UHE) in Algeria
Many international studies have shown the interest of prostate specific antigen (PSA) in prostate cancer monitoring, although it is not very specific to this pathology, it remains the best marker for the evaluation of pr...
Diabetic Kidney Disease: A New Concept for an Old Problem
Diabetes Mellitus (DM) is a growing worldwide epidemic. It was estimated that more than 366 million people would be affected. DM has spread its presence over the world due to lifestyle changes, increasing obesity and eth...
Bladder and Prostate Metastasis from Small Cell Lung Cancer: A Rare Entity
Bladder metastases from lung cancer are extremely rare; in some previously reported cases in with the primitive tumor was a lung adenocarcinoma, the finding of an intact epithelium overlying the bladder tumour was consid...